Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) have earned a consensus recommendation of “Moderate Buy” from the sixteen analysts that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $34.25.

DNLI has been the topic of several research reports. Leerink Partners dropped their price objective on shares of Denali Therapeutics from $40.00 to $35.00 and set an “outperform” rating on the stock in a report on Wednesday, April 22nd. Wall Street Zen upgraded shares of Denali Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 9th. Sanford C. Bernstein reiterated a “hold” rating on shares of Denali Therapeutics in a report on Monday. Stifel Nicolaus set a $41.00 target price on shares of Denali Therapeutics in a research report on Monday. Finally, Morgan Stanley reduced their target price on shares of Denali Therapeutics from $40.00 to $35.00 and set an “overweight” rating for the company in a research report on Friday, May 22nd.

Denali Therapeutics Price Performance

DNLI opened at $24.73 on Friday. Denali Therapeutics has a 12 month low of $12.58 and a 12 month high of $25.97. The stock has a market cap of $3.92 billion, a P/E ratio of -8.59 and a beta of 1.03. The company has a fifty day simple moving average of $20.50 and a 200 day simple moving average of $19.73. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Thursday, May 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.04. During the same quarter last year, the company earned ($0.78) earnings per share. On average, research analysts expect that Denali Therapeutics will post -2.77 EPS for the current year.

Hedge Funds Weigh In On Denali Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Headlands Technologies LLC purchased a new stake in Denali Therapeutics during the second quarter valued at $26,000. Johnson Financial Group Inc. bought a new stake in shares of Denali Therapeutics in the 3rd quarter valued at about $29,000. State of Wyoming bought a new stake in shares of Denali Therapeutics in the 2nd quarter valued at about $29,000. Fifth Third Bancorp purchased a new position in shares of Denali Therapeutics during the 1st quarter valued at approximately $55,000. Finally, Aster Capital Management DIFC Ltd purchased a new position in shares of Denali Therapeutics during the 4th quarter valued at approximately $57,000. Institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.